Acid Sphingomyelinase Deficiency (ASMD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Acid sphingomyelinase deficiency (ASMD), also known historically as Niemann-Pick disease types A, A/B, and B, is a lysosomal storage disease stemming from inadequate activity of the enzyme acid sphingomyelinase (ASM). This insufficiency results in the buildup of varying sphingomyelin levels within the body. ASMD is an inherited disorder caused by genetic variations that modify specific bodily processes, leading to the onset of the disease. The gene responsible for ASMD is referred to as SMPD1. This condition manifests with foam cell infiltration across different tissues, lipid storage, and a range of clinical symptoms that might overlap. Among these symptoms, pulmonary insufficiency, hepatosplenomegaly, and neurodegeneration stand out. The clinical presentations of ASMD serve as the primary indicators for differentiating this disease, which presents itself as a multi-organ disorder. While hepatosplenomegaly and lung dysfunction are prevalent features in ASMD, ASMD A also involves the central nervous system. ASMD A progresses rapidly and is frequently fatal within the initial years of life. On the other hand, ASMD B demonstrates a slower progression, featuring milder symptoms and often allowing patients to reach adulthood. The diagnosis of ASMD is established by identifying biallelic pathogenic variants in the SMPD1 gene using molecular genetic testing. Additionally, the assessment of residual acid sphingomyelinase enzyme activity, measuring less than 10% of controls, in peripheral blood lymphocytes or cultured skin fibroblasts confirms the diagnosis. Enzyme Replacement Therapy (ERT) utilizing Olipudase alfa (Xenpozyme®) effectively mitigates sphingomyelin accumulation in organs such as the lung, liver, and spleen, excluding the central nervous system.

 

Thelansis’s “Acid Sphingomyelinase Deficiency (ASMD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acid Sphingomyelinase Deficiency (ASMD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Acid Sphingomyelinase Deficiency (ASMD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Acid Sphingomyelinase Deficiency (ASMD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Acid Sphingomyelinase Deficiency (ASMD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Acid Sphingomyelinase Deficiency (ASMD), Acid Sphingomyelinase Deficiency (ASMD) market outlook, Acid Sphingomyelinase Deficiency (ASMD) competitive landscape, Acid Sphingomyelinase Deficiency (ASMD) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)